Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Immunocore (Nasdaq: IMCR) will present at the 25th Annual Needham Virtual Healthcare Conference with a fireside chat on April 13, 2026 at 3:00 p.m. EDT. The presentation will be webcast live and a replay will be available for a limited time via the company website.
Positive
- None.
Negative
- None.
News Market Reaction – IMCR
In the Apr 6 session, IMCR gained 3.60%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Clinical data preview | Positive | -2.3% | Planned five-year overall survival data presentation for KIMMTRAK at AACR 2026. |
| Mar 03 | Investor conferences | Neutral | -0.9% | Management participation in multiple March 2026 investor conferences with webcasts. |
| Feb 25 | Earnings and update | Positive | -4.5% | Reported FY2025 KIMMTRAK sales, narrowed net loss, and key 2026 data timelines. |
| Feb 18 | Earnings date set | Neutral | +0.4% | Announcement of Q4 and FY2025 results date and related investor call details. |
| Jan 30 | Leadership changes | Neutral | -1.4% | R&D leadership transition with internal promotions and emphasis on Phase 3 trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including earnings and scientific presentations, has often been followed by flat to negative next-day moves, even when the underlying updates were operationally positive.
Over the past few months, Immunocore has highlighted growing KIMMTRAK sales and advancing late-stage programs, with FY2025 revenue of $400.0M and multiple Phase 3 trials underway. Announcements about five-year KIMMTRAK survival data and participation in multiple investor conferences have not translated into strong positive price reactions, with several events followed by modest declines. The current Needham conference appearance fits this pattern of ongoing investor outreach and scientific visibility, adding another touchpoint with investors but not introducing new clinical or financial data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate in the 25th Annual Needham Virtual Healthcare Conference.
25th Annual Needham Virtual Healthcare Conference
Fireside Chat: Monday, April 13, 2026, at 3:00 p.m. EDT
The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore
Investor Relations
Morgan Morse
T: +1 (215) 384-4781
E: ir@immunocore.com
